NZ714273A - Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof - Google Patents

Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof

Info

Publication number
NZ714273A
NZ714273A NZ714273A NZ71427314A NZ714273A NZ 714273 A NZ714273 A NZ 714273A NZ 714273 A NZ714273 A NZ 714273A NZ 71427314 A NZ71427314 A NZ 71427314A NZ 714273 A NZ714273 A NZ 714273A
Authority
NZ
New Zealand
Prior art keywords
interest
compound
combination
pharmaceutical composition
nanoparticle
Prior art date
Application number
NZ714273A
Other languages
English (en)
Inventor
Marie-Edith Meyre
Laurent Levy
Agnès Pottier
Audrey Darmon
Matthieu Germain
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of NZ714273A publication Critical patent/NZ714273A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ714273A 2013-05-30 2014-05-30 Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof NZ714273A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361828794P 2013-05-30 2013-05-30
EP13305712 2013-05-30
PCT/EP2014/061296 WO2014191569A1 (en) 2013-05-30 2014-05-30 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
NZ714273A true NZ714273A (en) 2019-04-26

Family

ID=48656009

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ714273A NZ714273A (en) 2013-05-30 2014-05-30 Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof

Country Status (17)

Country Link
US (2) US10413509B2 (enExample)
EP (1) EP3003288A1 (enExample)
JP (1) JP6387400B2 (enExample)
KR (1) KR102245421B1 (enExample)
CN (2) CN105407878A (enExample)
AU (1) AU2014273043B2 (enExample)
BR (1) BR112015029853A2 (enExample)
CA (1) CA2913023C (enExample)
EA (1) EA038671B1 (enExample)
HK (1) HK1222563A1 (enExample)
MA (1) MA38687A1 (enExample)
MX (1) MX376269B (enExample)
NZ (1) NZ714273A (enExample)
SG (1) SG11201509436TA (enExample)
UA (1) UA116380C2 (enExample)
WO (1) WO2014191569A1 (enExample)
ZA (1) ZA201509307B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201403096VA (en) 2011-12-16 2014-07-30 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
MA38687A1 (fr) 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
US11304902B2 (en) 2014-11-25 2022-04-19 Curadigm Sas Pharmaceutical compositions, preparation and uses thereof
TW201628656A (zh) * 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備與用途
ES2951598T3 (es) 2014-11-25 2023-10-23 Curadigm Sas Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos
EP3229843B1 (en) 2014-11-25 2020-01-01 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
WO2016134134A1 (en) * 2015-02-19 2016-08-25 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
CN105055447B (zh) * 2015-06-23 2018-03-13 中南大学湘雅二医院 氧化铁纳米颗粒用于制备改善厄洛替尼耐药性药物的应用
WO2020006493A1 (en) * 2018-06-29 2020-01-02 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
CN108969757B (zh) * 2018-07-11 2021-07-27 浙江大学 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用
CN110498607B (zh) * 2019-08-21 2022-03-08 中国科学院上海硅酸盐研究所 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) * 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US20030186869A1 (en) * 1990-05-14 2003-10-02 George Poiani Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US6686332B1 (en) * 1993-10-15 2004-02-03 Xoma Corporation Method of treating depressed reticuloendothelial system function
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
AU4821697A (en) 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) * 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
JP2001515035A (ja) 1997-08-19 2001-09-18 ワーナー−ランバート・カンパニー 薬剤の経口生体利用性を高めるベルガモッチンを含有する組成物
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
ES2253398T3 (es) * 2000-06-30 2006-06-01 Inex Pharmaceuticals Corp. Camptotecinas liposomales mejoradas y sus usos.
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
US9750821B2 (en) 2003-12-22 2017-09-05 Bracco Suisse S.A. Gas-filled microvesicle assembly for contrast imaging
EP1720521A4 (en) * 2004-02-10 2008-11-05 Barnes Jewish Hospital IMPROVED EFFICIENCY AND SAFETY OF TARGETED MEANS WITH DECOY SYSTEMS
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) * 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
EP2019665B1 (en) 2006-05-04 2018-09-19 Reformpharm Pty Ltd Drug release from nanoparticle-coated capsules
AU2008288917A1 (en) 2007-08-21 2009-02-26 Alza Corporation Liposome compositions for in vivo administration of boronic acid compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US20100272639A1 (en) * 2007-12-21 2010-10-28 John Robert Dutcher Polysaccharide nanoparticles
CA2716347C (en) 2008-02-21 2017-06-20 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
EP2275137A1 (en) * 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
AU2011215557B2 (en) * 2010-02-09 2016-03-10 Sangamo Therapeutics, Inc. Targeted genomic modification with partially single-stranded donor molecules
EP2537530A4 (en) 2010-02-17 2015-12-16 Nat Univ Corp Univ Kobe RADIATION MEANS
BR112012024349A2 (pt) 2010-03-26 2016-05-24 Abraxis Bioscience Llc métodos de tratamento de carcinoma hepatocelular
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
WO2012051220A1 (en) 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
EP3192800A1 (en) 2010-12-17 2017-07-19 Arrowhead Pharmaceuticals, Inc. Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
EP2670394B1 (en) 2011-01-31 2018-11-21 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
EP2670393B8 (en) 2011-01-31 2016-10-05 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
US20120237566A1 (en) * 2011-03-15 2012-09-20 Venture Isles, LLC Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
CN102532154B (zh) 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
MA38687A1 (fr) 2013-05-30 2017-12-29 Nanobiotix Composition pharmaceutique, préparation et utilisations de celle-ci
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
TW201628656A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備與用途
EP3229843B1 (en) 2014-11-25 2020-01-01 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
US11304902B2 (en) 2014-11-25 2022-04-19 Curadigm Sas Pharmaceutical compositions, preparation and uses thereof
CN107106505A (zh) 2014-11-25 2017-08-29 纳米生物技术公司 药物组合物、其制备和用途
ES2951598T3 (es) 2014-11-25 2023-10-23 Curadigm Sas Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos

Also Published As

Publication number Publication date
US20160184225A1 (en) 2016-06-30
US11357724B2 (en) 2022-06-14
HK1222563A1 (zh) 2017-07-07
US10413509B2 (en) 2019-09-17
MX376269B (es) 2025-03-07
CA2913023C (en) 2021-06-08
JP6387400B2 (ja) 2018-09-05
AU2014273043B2 (en) 2019-02-07
SG11201509436TA (en) 2015-12-30
CN105407878A (zh) 2016-03-16
MA38687A1 (fr) 2017-12-29
ZA201509307B (en) 2017-04-26
KR20160013212A (ko) 2016-02-03
CA2913023A1 (en) 2014-12-04
MX2015016456A (es) 2016-03-03
US20200009050A1 (en) 2020-01-09
EA201592279A1 (ru) 2016-06-30
BR112015029853A2 (pt) 2017-07-25
AU2014273043A1 (en) 2015-12-03
EA038671B1 (ru) 2021-10-01
JP2016522833A (ja) 2016-08-04
KR102245421B1 (ko) 2021-04-29
CN112107558A (zh) 2020-12-22
WO2014191569A1 (en) 2014-12-04
UA116380C2 (uk) 2018-03-12
EP3003288A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
MX2021010595A (es) Composicion farmaceutica, preparacion y usos de la misma.
MX2017006813A (es) Composicion farmaceutica, preparacion y usos de la misma.
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
MX355330B (es) Formas cristalinas de compuestos terapeuticos y sus usos.
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
HK1218560A1 (zh) 组成与方法
HK1212207A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
HK1198475A1 (en) Heterocyclic compounds and uses thereof
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
MY179605A (en) Use of benzimidazole-proline derivatives
GB2489382A (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2016025933A3 (en) Substituted polycyclic antibacterial compounds
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
PH12015502747A1 (en) Novel compounds for the treatment of cancer
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
WO2014182789A3 (en) Radiomitigating pharmaceutical formulations
IN2013MU01177A (enExample)
NZ704342A (en) Compositions comprising spicamycin derivatives and methods of use thereof
PH12015502727A1 (en) Methods and compositions for enhancing cognitive performance
PH12021551310A1 (en) Antimicrobial compositions comprising modified clay and biphenol
TR201905694T4 (tr) Aripiprazol ön ilaç bileşimleri.

Legal Events

Date Code Title Description
PSEA Patent sealed
ASS Change of ownership

Owner name: CURADIGM SAS, FR

Effective date: 20191128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2021 BY IPAN GMBH

Effective date: 20200518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2022 BY IPAN GMBH

Effective date: 20210512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2023 BY IPAN GMBH

Effective date: 20220509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2024 BY IPAN GMBH

Effective date: 20230509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2025 BY IPAN GMBH

Effective date: 20240509

ASS Change of ownership

Owner name: NANOBIOTIX, FR

Effective date: 20250227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 MAY 2026 BY PAVIS PAYMENT GMBH

Effective date: 20250514